Arcturus Therapeutics Holdings Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual report; the filing text provided does not give standalone fourth-quarter financial results. Arcturus is a clinical-stage mRNA medicines and vaccine company, with programs in infectious-disease vaccines and rare liver and respiratory diseases. It had no approved products and no product-sales revenue.
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Total revenue | $206.0 million | $12.4 million |
| Operating expenses | $193.8 million | $215.2 million |
| Income (loss) from operations | $12.2 million | $(202.9) million |
| Net income (loss) | $9.3 million | $(203.7) million |
| Operating cash flow | $32.0 million | $(135.0) million |
| Capital expenditures | $7.7 million | $3.4 million |
- Revenue was predominantly collaboration revenue ($205.8 million); grant revenue was $0.2 million. The filing reports no product-sales revenue.
- Reported operating and net margins were approximately 5.9% and 4.5%, respectively, calculated from reported figures. These results reflect collaboration and other revenue, not product sales.
- At year-end, unrestricted cash and cash equivalents were $391.9 million; cash, cash equivalents and restricted cash totaled $394.0 million. Current assets were $403.3 million and current liabilities $127.0 million, implying working capital of about $276.3 million.
- Year-end debt was $60.7 million, all classified as current; long-term debt was zero. In March 2023, the company paid off its Western Alliance loan for about $7.36 million. Separately, it paid $17.1 million to Singapore’s EDB and received forgiveness of approximately $33.3 million of the Singapore Loan, including accrued interest.
- The filing states that management believed available working capital could fund operations for at least 12 months, subject to assumptions including anticipated partner funding and no significant unforeseen expenses.
Changes versus FY2021
- Revenue increased by $193.6 million, chiefly reflecting CSL Seqirus collaboration revenue, higher Vinbiocare revenue, recognition of a $12.5 million Israel Ministry of Health reservation payment, and Janssen revenue recognized during the wind-down of that agreement.
- Arcturus recorded its first annual net income since inception, compared with a $203.7 million net loss in FY2021. The filing attributes the turnaround primarily to collaboration revenue, including the CSL agreement; it does not represent a change to product-sales status.
- Net R&D expense decreased by $26.0 million to $147.8 million, mainly due to lower manufacturing and clinical costs and higher collaboration/grant offsets. G&A expense rose $4.6 million to $46.1 million.
- Operating cash flow improved by $167.0 million year over year. The company ended the year with $21.4 million more in cash, cash equivalents and restricted cash than at the start of the year.
Business developments, outlook and risks
- CSL Seqirus: The global vaccine collaboration became effective in December 2022 and covered COVID-19, influenza, three other respiratory infectious diseases, and non-exclusive pandemic-preparedness rights. Arcturus received a $200 million upfront payment; $154.4 million was recognized as FY2022 revenue. The company may receive more than $1.3 billion in development milestones, up to $3.0 billion in commercial milestones, a 40% share of COVID-19 net profits, and royalties on other covered vaccines. These potential amounts are conditional, not assured. In March 2023, $90 million of development milestones became due; this was not included in FY2022 transaction price or revenue.
- Pipeline: ARCT-154 met its primary efficacy endpoint in a Vietnam Phase 3 study; reported efficacy was 55.0% against COVID-19 overall and 95.3% against severe or fatal disease during a period when Delta predominated. A Japan Phase 3 booster study completed enrollment in February 2023. ARCT-810’s Phase 2 study dosed its first patient in December 2022; the company expected interim data in the second half of 2023. ARCT-032 began first-in-human dosing, with two cohorts dosed as reported in the filing.
- Funding and guidance: Arcturus expects continued losses over the long term and said R&D and G&A costs were expected to increase. It cited milestone execution, additional financing or partnerships as important to longer-term funding. A $63.2 million BARDA cost-reimbursement contract supports pandemic-influenza development over three years; it is not a vaccine purchase commitment. The company forecast manufacturing capacity above 200 million COVID-vaccine doses annually by the end of 2023, subject to manufacturing partners and ongoing transfers.
- Principal risks: No candidate had marketing approval. ARCT-154’s regulatory path, including acceptance of foreign trial data and possible requirements for updated vaccine composition, remained uncertain. COVID-19 market demand and pricing could decline; the CSL collaboration can be terminated in specified circumstances, including by CSL for convenience. The company also depends on external manufacturers and clinical contractors, faces mRNA competition and intellectual-property risks, and may need additional capital.
- Other notable items: The Vinbiocare license and supply agreements were terminated in 2022 and replaced with study support arrangements; Arcturus recorded $24.6 million of Vinbiocare revenue and accrued related future payment obligations. Janssen terminated its collaboration effective December 30, 2022. The filing reports no current legal proceedings. Management concluded disclosure controls and internal control over financial reporting were effective; the independent auditor did not attest to internal control effectiveness.
Important facts for investors to verify
- How much of the $200 million CSL upfront payment was recognized as revenue, remains deferred, or is subject to future obligations—and the timing and conditions for the $90 million milestone payment and other potential milestones.
- Whether the March 2023 Singapore Loan forgiveness and Western Alliance payoff were completed on the disclosed terms, and the resulting post-year-end cash and debt balances.
- Regulatory progress and complete safety, efficacy and immunogenicity data for ARCT-154, including the Vietnam follow-up and Japan study results.
- Actual cash burn and funding runway as collaboration receipts, development spending, and clinical and manufacturing costs evolve.
- Execution and termination terms across CSL, Vinbiocare and BARDA arrangements, as well as manufacturing capacity, supply-chain and intellectual-property risks.